Companies included in XBI Page 2
This is XBI's own dated portfolio constitution. Share counts are the calculation basis for constituent revenue and earnings analytics; rounded weights are reference values only. This page shows positions 101–158 of 158.
| Ticker | Issuer | Shares owned | Unit | Reported weight |
|---|---|---|---|---|
| TYRA | Tyra Biosciences Inc | 655,457 | NS | 0.337671% |
| GERN | Geron Corp | 16,613,693 | NS | 0.332969% |
| Day One Biopharmaceuticals Inc | Day One Biopharmaceuticals Inc | 1,113,401 | NS | 0.321091% |
| PGEN | Precigen Inc | 6,004,794 | NS | 0.312579% |
| VIR | Vir Biotechnology Inc | 2,527,795 | NS | 0.30465% |
| KalVista Pharmaceuticals Inc | KalVista Pharmaceuticals Inc | 1,077,952 | NS | 0.291873% |
| CTMX | CytomX Therapeutics Inc | 4,511,036 | NS | 0.285184% |
| ANNX | Annexon Inc | 3,823,368 | NS | 0.28491% |
| KURA | Kura Oncology Inc | 2,523,230 | NS | 0.27593% |
| INBX | Inhibrx Biosciences Inc | 296,581 | NS | 0.268199% |
| SLS | SELLAS Life Sciences Group Inc | 4,689,810 | NS | 0.266837% |
| JANX | Janux Therapeutics Inc | 1,424,540 | NS | 0.266343% |
| CMPX | Compass Therapeutics Inc | 3,684,989 | NS | 0.262206% |
| SVRA | Savara Inc | 3,554,970 | NS | 0.261084% |
| RIGL | Rigel Pharmaceuticals Inc | 708,776 | NS | 0.257791% |
| SANA | Sana Biotechnology Inc | 6,650,475 | NS | 0.25763% |
| CGEM | Cullinan Therapeutics Inc | 1,307,461 | NS | 0.249904% |
| SPRY | ARS Pharmaceuticals Inc | 2,213,506 | NS | 0.239082% |
| ZBIO | Zenas Biopharma Inc | 906,255 | NS | 0.238313% |
| XNCR | Xencor Inc | 1,422,163 | NS | 0.2307% |
| REPL | Replimune Group Inc | 2,198,386 | NS | 0.226213% |
| SION | Sionna Therapeutics Inc | 416,630 | NS | 0.224666% |
| VOR | Vor BioPharma Inc | 932,400 | NS | 0.223742% |
| AVBP | ArriVent Biopharma Inc | 701,088 | NS | 0.217556% |
| IRWD | Ironwood Pharmaceuticals Inc | 3,999,224 | NS | 0.188814% |
| BCAX | Bicara Therapeutics Inc | 701,643 | NS | 0.187716% |
| PRME | Prime Medicine Inc | 3,979,993 | NS | 0.1863% |
| ALT | Altimmune Inc | 4,353,091 | NS | 0.180343% |
| ABSI | Absci Corp | 4,448,453 | NS | 0.179507% |
| EBS | Emergent BioSolutions Inc | 1,572,925 | NS | 0.175605% |
| ALLO | Allogene Therapeutics Inc | 5,212,606 | NS | 0.171079% |
| PURR | Hyperliquid Strategies Inc | 2,451,336 | NS | 0.167831% |
| FDMT | 4D Molecular Therapeutics Inc | 1,318,068 | NS | 0.165059% |
| VNDA | Vanda Pharmaceuticals Inc | 1,704,031 | NS | 0.158382% |
| RGNX | REGENXBIO Inc | 1,363,810 | NS | 0.153727% |
| LXEO | Lexeo Therapeutics Inc | 1,862,707 | NS | 0.143816% |
| VSTM | Verastem Inc | 2,014,499 | NS | 0.143613% |
| ABUS | Arbutus Biopharma Corp | 2,268,065 | NS | 0.137284% |
| MYGN | Myriad Genetics Inc | 2,160,321 | NS | 0.130762% |
| Prothena Corp PLC | Prothena Corp PLC | 983,448 | NS | 0.128579% |
| OCGN | Ocugen Inc | 5,222,819 | NS | 0.127155% |
| Rocket Pharmaceuticals Inc | Rocket Pharmaceuticals Inc | 2,606,982 | NS | 0.125537% |
| MDXG | MiMedx Group Inc | 2,282,660 | NS | 0.12128% |
| AKBA | Akebia Therapeutics Inc | 6,038,997 | NS | 0.11291% |
| AVXL | Anavex Life Sciences Corp | 2,653,883 | NS | 0.10959% |
| CONTRA METSERA INC | CONTRA METSERA INC | 1,530,714 | NS | 0.100888% |
| IVVD | Invivyd Inc | 5,654,625 | NS | 0.098878% |
| CATX | Perspective Therapeutics Inc | 1,713,495 | NS | 0.09611% |
| State Street Global Advisors | State Street Global Advisors | 4,700,194.36 | NS | 0.063222% |
| DMRA | Damora Therapeutics Inc | 93,797 | NS | 0.032677% |
| CONTRA AKERO THERAPEUT | CONTRA AKERO THERAPEUT | 2,033,975 | NS | 0.017783% |
| CONTRA INHIBRX INC | CONTRA INHIBRX INC | 1,645,973 | NS | 0.014391% |
| CONTRA MIRATI THERAPEU | CONTRA MIRATI THERAPEU | 1,369,552 | NS | 0.012895% |
| CONTRA VERVE THERAPEUT | CONTRA VERVE THERAPEUT | 900,273 | NS | 0.007629% |
| CONTRA BLUEPRINT MEDIC | CONTRA BLUEPRINT MEDIC | 756,469 | NS | 0.004681% |
| State Street Global Advisors | State Street Global Advisors | 36,550.53 | NS | 0.000492% |
| OMNIAB INC | OMNIAB INC | 161,959 | NS | 0% |
| OMNIAB INC | OMNIAB INC | 161,959 | NS | 0% |
SEC N-PORT snapshot as of .